Chris Ballas

Chris brings over 25 years of experience working on cell and gene therapies with expertise in research, development, testing, and manufacturing of viral vectors and cell therapies. Currently, he is the SVP of Manufacturing for Innovative Cellular Therapeutics, where he specializes in autologous ex vivo lentiviral vector stem cell and CAR-T cell therapies.

Chris has served in consulting/senior and executive roles for multiple gene therapy companies and recently co-developed an ultra-high throughput microinjection device and co-founded Basilard Biotech in order to commercialize this technology. He holds a PhD in Cellular and Molecular Pathology from Vanderbilt University School of Medicine and was a Children’s Brittle Bone Foundation fellow during a post-doctoral fellowship at Case Western Reserve University School of Medicine.